Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 373 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Locations: - Kingman Regional Medical Center — Kingman, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Tower Cancer Research Foundation — Beverly Hills, California
+ 179 more sites in the U.S.
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Locations: - Cancer Center at Saint Joseph's — Phoenix, Arizona
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Los Angeles General Medical Center — Los Angeles, California
+ 96 more sites in the U.S.
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Locations: - Clinical Study Site — Goodyear, Arizona
- Clinical Study Site — Beverly Hills, California
- Clinical Study Site — Cerritos, California
+ 41 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- UCHealth University of Colorado Hospital — Aurora, Colorado
- UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
+ 36 more sites in the U.S.
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused telisotuzumab adizutecan to …
Sponsor: AbbVie
NCT ID: NCT06614192
Locations: - City of Hope National Medical Center /ID# 267875 — Duarte, California
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 270655 — Irvine, California
- USC Norris Comprehensive Cancer Center /ID# 268131 — Los Angeles, California
+ 21 more sites in the U.S.
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Locations: - City of Hope — Arcadia, California
- Yale Cancer Center — New Haven, Connecticut
- Georgetown University — Washington D.C., District of Columbia
+ 15 more sites in the U.S.
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Locations: - Yale University — New Haven, Connecticut
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
+ 6 more sites in the U.S.
Phase 3 Recruiting Industry
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Sponsor: Surgimab
NCT ID: NCT03659448
Locations: - City of Hope National Medical Center — Duarte, California
- Moores Cancer Center - UCSD Health — La Jolla, California
- Cleveland Clinic Florida — Weston, Florida
+ 3 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance …
Sponsor: Massachusetts General Hospital
NCT ID: NCT03803553
Locations: - Massachusetts General Hospital — Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medical College — New York, New York
Phase 3 Recruiting Academic/Other
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocar…
Sponsor: Georgetown University
NCT ID: NCT05482516
Locations: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
- Medstar Washington Hospital Center — Washington D.C., District of Columbia
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 3 Recruiting Academic/Other
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (…
Sponsor: Roswell Park Cancer Institute
NCT ID: NCT06563388
Locations: - Roswell Park Comprehensive Cancer Center — Buffalo, New York